Oct 10 (Reuters) – U.S. regulators on Friday approved Gilead Sciences Inc’s all-oral hepatitis C drug, clearing the way for the company to increase its revenue from sales of treatments for the liver-destroying viral infection.
Source: Financials
Author
Harry Joiner
“… a dominant recruiter in the client-side multichannel ecommerce space …” — SearchEngineWatch.com